Quest Partners LLC Acquires Shares of 14,055 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quest Partners LLC bought a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 14,055 shares of the life sciences company’s stock, valued at approximately $255,000.

Several other hedge funds and other institutional investors also recently modified their holdings of IART. Blue Trust Inc. grew its holdings in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC grew its position in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after buying an additional 425 shares during the last quarter. KBC Group NV raised its position in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in shares of Integra LifeSciences in the third quarter worth approximately $73,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Integra LifeSciences in the 2nd quarter worth approximately $114,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $23.70 on Wednesday. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The stock’s 50 day moving average is $20.22 and its 200-day moving average is $24.02. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -263.30, a PEG ratio of 0.80 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the firm earned $0.76 earnings per share. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IART shares. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Citigroup lifted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Finally, Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $24.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.